Tuesday, March 15, 2022 6:17:27 PM
Diver, they were actually early on the 10-K, roughly out when Nasdaq companies were due, they could have waited for the end of this month as an OTC. Perhaps they're acting like a Nasdaq or NYSE company because that's where they intend to be. I suspect in time they'll need to separate the CEO and CFO before moving to a bigger exchange.
I've previously heard that your estimated size for the BLA is about right, to me that's a very sad fact. I can't say that what's in the Journal by itself should be sufficient, I don't think the Journal will cover the production or distribution of the vaccine, but the Journal, plus something the size of the Journal on production, storage, and distribution of the vaccine ought to be sufficient, the whole thing ought to be under 100 pages, not perhaps a million.
If we ever want to bring the cost of drug development down, such changes in the way we do business are sorely needed. I would suspect that if we could put a dollar price on each page in the BLA it would come down to somewhere between $10 and $100 a page or more. Look at all the trees we could save.
Gary
I've previously heard that your estimated size for the BLA is about right, to me that's a very sad fact. I can't say that what's in the Journal by itself should be sufficient, I don't think the Journal will cover the production or distribution of the vaccine, but the Journal, plus something the size of the Journal on production, storage, and distribution of the vaccine ought to be sufficient, the whole thing ought to be under 100 pages, not perhaps a million.
If we ever want to bring the cost of drug development down, such changes in the way we do business are sorely needed. I would suspect that if we could put a dollar price on each page in the BLA it would come down to somewhere between $10 and $100 a page or more. Look at all the trees we could save.
Gary
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
